Target intelligence / Profile preview

T-cell receptor recognizing Yersinia pestis F1 and V antigens (F1/V-specific TCR)

Target
F1/V-specific TCR
Molecular classification
Receptor, T-cell receptor
01

Overview

T-cell receptors (TCRs) recognizing F1- and V-derived peptides presented on MHC class II are specialized immune receptors that play a pivotal role in the defense against Yersinia pestis, the causative agent of plague [1]. The F1 (Caf1) and V (LcrV) antigens are critical virulence factors; F1 forms a protective capsule, while V is essential for the injection of effector proteins into host cells via the type III secretion system [2]. These TCRs are expressed on the surface of CD4+ T lymphocytes and are responsible for identifying specific bacterial peptide fragments displayed by Major Histocompatibility Complex (MHC) class II molecules on antigen-presenting cells [3]. Upon recognition, the TCR initiates a signaling cascade that leads to T-cell activation, proliferation, and the secretion of pro-inflammatory cytokines like interferon-gamma (IFN-γ), which are necessary for activating macrophages to kill the intracellular bacteria [4]. Because of their central role in protective immunity, these TCR-peptide-MHC interactions are the primary focus of subunit vaccine development, such as the rF1-V fusion protein vaccine, which aims to elicit a robust and memory-capable T-cell response [5]. A significant challenge in targeting these receptors is the high degree of MHC polymorphism in human populations, which can lead to variable recognition of specific F1 and V epitopes across different individuals [6].

Other names
F1-specific T-cell receptorV-antigen specific T-cell receptorLcrV-specific TCRCaf1-specific TCRYersinia pestis antigen-specific T-cell receptor
02

Mechanism of action

Vaccines containing F1 and V antigens prime the immune system to generate a population of CD4+ T cells expressing these specific TCRs; upon subsequent infection, these TCRs recognize the peptide-MHC II complexes on antigen-presenting cells, triggering a rapid Th1-mediated immune response and macrophage activation to clear Yersinia pestis.

03

Biological functions

Immune responseAntigen recognitionT-cell activationCytokine production
04

Disease associations

InfectionPlague
05

Safety considerations

MHC restriction (efficacy varies by HLA type)Potential for immune evasion via antigen mutationRisk of inadequate response in immunocompromised individuals
06

Interacting drugs

rF1-V vaccine

1 more in the full profile.

07

Biomarkers

Interferon-gamma (IFN-g)MHC class II tetramersCD4+ T-cell proliferationTNF-alphaCD154 expression

Beyond the preview

Go deeper on T-cell receptor recognizing Yersinia pestis F1 and V antigens (F1/V-specific TCR).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on T-cell receptor recognizing Yersinia pestis F1 and V antigens (F1/V-specific TCR).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call